J&J's Multiple Myeloma Duo Aces Phase 3 Trial

J&J's multiple myeloma duo aces phase 3 trial

Two of Johnson & Johnson's multiple myeloma bispecifics, Tecvayli and Talvey, have dramatically improved survival when used as a second-line regimen.

Relapsed/Refractory Multiple Myeloma: Future Directions for T-Cell–Redirecting Therapies

Dr. Ajai Chari and Dr. Rahul Banerjee conclude the discussion by exploring future opportunities to further improve outcomes for patients with relapsed/refractory multiple myeloma (RRMM).

Stopping myeloma maintenance therapy at 2 years is safe: Study

Maintenance therapy for myeloma can be stopped after two years without raising the risk of disease progression or death, a new study shows. “For years, patients and clinicians have been hesitant to stop lenalidomide maintenance because we didn’t know how long was required for optimal benefit,” Shaji Kumar, lead author of the study at Mayo Clinic, said in a press release. “Our trial results show that two years is sufficient and that continuing th…